IgM multiple myeloma: Report of four cases and review of the literature

References

• Kyle R A. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin N Am 1992; 6: 347–358
   PubMed Web of Science ®Google Scholar
• De Gramont A, Grosbois B, Michaux J L, Peny A M, Pollet J P, Smadja N, et al. IgM myeloma: 6 cases and a review of literature. La Revue de Medicine Interne 1990; 11: 13–18
   PubMed Web of Science ®Google Scholar
• Grogan T M, Spier C M. The B cell immunoproliferative disorders, including multiple myeloma and amyloidosis. Neoplastic hematopathology, D M Knowels. Williams and Wilkins, Baltimore 1992; 1235–1265
   Google Scholar
• Dimopoulos M A, Panayiotidis P, Moulopoulos L A, Sfikakis P, Dalakas M. Waldenström's macroglobulinemia: clinical features, complications and management. J Clin Oncol 2000; 18: 214–226
   PubMed Web of Science ®Google Scholar
• Zarrabi M H, Stark R S, Kane P, Dannaher Cl, Chandors S. IgM Myeloma, a distinct entity in the spectrum of B cell neoplasia. Am J Clin Pathol 1981; 75: 1–10
   PubMed Web of Science ®Google Scholar
• Bachman R. The diagnostic significance of the serum concentration of pathological proteins (M-components). Acta Med Scand 1965; 178: 801–808
   PubMed Web of Science ®Google Scholar
• MacLennan I CM. In which cells does neoplastic transformation occur in myelomatosis?. Curr Topics Microbiol Immunol 1992; 182: 209–213
   PubMedGoogle Scholar
• Kyle R A. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987; 62: 719–731
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamamura F, Motoyama H. IgM myeloma: its distinction from Waldenström's macroglobulinemia. Acta Pathol Jap 1986; 36: 1553–1563
   PubMedGoogle Scholar
• Haghighi B, Yanagihara R, Cornbleet J. IgM myeloma: case report with immunophenotypic profile. Am J Hematol 1998; 59: 302–308
   PubMed Web of Science ®Google Scholar
• Ho C L, Chen Y C, Yiang Y T, Kao W Y. Mandibular mass as the presenting manifestation of IgM myeloma in a 22-years old man. Ann Hematol 1999; 78: 93–95
   PubMed Web of Science ®Google Scholar
• Kondo H, Yokoyama K. IgM myeloma: different features from multiple myeloma and macroglobulinaemia. Eur J Haematol 1999; 63: 366–368
   PubMed Web of Science ®Google Scholar
• Dierlamm T, Laack E, Dierlamm J, Fiedler W, Hossfeld D K. IgM myeloma: a report of four cases. Ann Hematol 2002; 81: 136–139
   PubMed Web of Science ®Google Scholar
• Chenal A, Taher A, Shamseddine A. IgM myeloma and Waldenström's macroglobulinemia: a distinct clinical feature histology, immunophenotype, and chromosomal abnormality. Clin Lab Haematol 2003; 25: 187–190
   PubMedGoogle Scholar
• Stellmacher F, Sotlar K, Balleisen L, Valent P, Horny H. Bone marrow mastocytosis associated with IgM kappa plasmacell myeloma. Leuk Lymphoma 2004; 45: 801–805
   PubMed Web of Science ®Google Scholar
• Durie B G, Salmon S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Kyle R A, Therneau T M, Rajkumar S V, Remstein E D, Offord J R, Larson D R, et al. Long term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102: 3759–3764
   PubMed Web of Science ®Google Scholar
• The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757
   PubMed Web of Science ®Google Scholar
• Berman H H. Waldenström's macroglobulinemia with lytic osseous lesions and plasma-cell morphology: report of a case. Am J Clin Pathol 1974; 63: 397–402
   Web of Science ®Google Scholar
• Weick J K, Crowley J J, Hussein M A, Moore D F, Barlogie B. The evaluation of gemcitabine in resistant or relapsing multiple myeloma phase II: a Southwest Oncology Group study. Invest New Drugs 2002; 20: 117–121
   PubMed Web of Science ®Google Scholar
• Offidani M, Miele A, Corvatta L, Marconi M, Malerba L, Olivieri A, et al. Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma. Leuk Lymphoma 2002; 43: 1273–1279
   PubMed Web of Science ®Google Scholar
• Leleu X, Troncy J, Bouafia F, Michallet M, Facon T, Dumontet C. Evaluation of gemcitabine in relapsed or refractory multiple myeloma. Haematologica 2004; 89: ELT15
   PubMedGoogle Scholar
• Avet-Louseau H, Garand R, Lode L, Harousseau J L, Bataille R. Intergroupe Francophone du Myelome. Translocation t(11;14)(q13; q32) is the hallmark of IgM, IgE and nonsecretory multiple myeloma variants. Blood 2003; 101: 1570–1571
   PubMed Web of Science ®Google Scholar
• Annibali O, Petrucci M T, Martini V, Tirindelli M C, Levi A, Fossati C, et al. Treatment of 72 newly diagnosed Waldenström's macroglobulinemia patients with oral Melphalan, Cyclophosfamide and Prednisone (MCP): results and cost analysis. Cancer 2005; 103: 582–587
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Merlini G, Leblond V, Anagnostopoulos A, Alexanian R. How we treat Waldenström's macroglobulinemia. Haematologica 2005; 90: 117–125
   PubMed Web of Science ®Google Scholar
• Lin P, Owen R, Tricot G, Wilson C S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Patholol 2004; 121: 482–488
   PubMed Web of Science ®Google Scholar